SYSTEMS PHARMACOLOGY OF CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR CORRECTORS AND POTENTIATORS
Grant number: 1157287 | Funding period: 2019 - 2023
Related publications (5)
Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung.
Fiona Qiu, Mark D Habgood, Yifan Huang, Katarzyna M Dziegielewska, Sam Toll, Elena K Schneider-Futschik
BACKGROUND: The potential effects of ivacaftor during pregnancy and breastfeeding on the offspring are still unknown. This study a..
Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders
Elena K Schneider-Futschik, Felisa Reyes-Ortega
Nanomaterials provide enormous opportunities to overcome the limitations of conventional ocular delivery systems, such as low ther..
Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
Kiera H Harwood, Rachel M McQuade, Andrew Jarnicki, Elena K Schneider-Futschik
Cystic fibrosis (CF) is caused by a defect in the cystic fibrosis transmembrane conductance regulator protein (CFTR) which instiga..
Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis
Marsha Tan, Felisa Reyes-Ortega, Elena K Schneider-Futschik
Magnetic nanoparticles have been largely applied to increase the efficacy of antibiotics due to passive accumulation provided by e..
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation
Drishti P Ghelani, Elena K Schneider-Futschik
Pharmacological correction of the defective ion channel with cystic fibrosis transmembrane conductance regulator (CFTR) has become..